New stimulant formulations for pediatric attention-deficit/hyperactivity disorder: a case-based approach for the primary care provider. Issue 1 (February 2019)

• Record Type: Journal Article
• Authors: Partain, Paige I.; White, Jacob; Hammerness, Paul
• Is Part Of: Current opinion in pediatrics. Volume 31:Issue 1(2019:Feb.)
• Publication Date: 2019-02
• Subjects: amphetamine -- methylphenidate -- pediatric attention-deficit/hyperactivity disorder -- stimulant therapy; Pediatrics -- Periodicals; Pediatrics -- Periodicals -- Bibliography -- Periodicals; 618.92
• DOI: 10.1097/MOP.0000000000000718
• Languages: English
• ISSNs: 1040-8703

Abstract

Abstract : Purpose of review: To provide an up-to-date clinical review of U.S. Food and Drug Administration (FDA)-approved stimulant medications for attention-deficit/hyperactivity disorder (ADHD), including a framework for individualized treatment by primary care pediatric providers. Recent findings: Stimulant medications are first-line agents for pediatric ADHD. Since 2012, 11 novel stimulant medications have been approved by the FDA for the treatment of ADHD. Because of an expanded formulary of available methylphenidate-based and amphetamine-based stimulants, primary care providers may be unfamiliar with some novel medications outside a select formulary. Summary: The current broad formulary of methylphenidate-based and amphetamine-based stimulants provides primary care clinicians with a greater opportunity for personalized medicine within the patient-centered medical home. Through a systematic review of prior relevant medication trials, a consideration of daily symptom burden and thoughtful pragmatics, primary care providers can offer a more precise, customized stimulant treatment.